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Abstract. Predicting clinical outcome is remarkably important but chal-
lenging. Research efforts have been paid on seeking significant biomark-
ers associated with the therapy response or/and patient survival. How-
ever, these biomarkers are generally costly and invasive, and possibly
dissatifactory for novel therapy. On the other hand, multi-modal, het-
erogeneous, unaligned temporal data is continuously generated in clinical
practice. This paper aims at a unified deep learning approach to predict
patient prognosis and therapy response, with easily accessible data, e.g.,
radiographics, laboratory and clinical information. Prior arts focus on
modeling single data modality, or ignore the temporal changes. Impor-
tantly, the clinical time series is asynchronous in practice, i.e., recorded
with irregular intervals. In this study, we formalize the prognosis model-
ing as a multi-modal asynchronous time series classification task, and
propose a MIA-Prognosis framework with Measurement, Interven-
tion and Assessment (MIA) information to predict therapy response,
where a Simple Temporal Attention (SimTA) module is developed to
process the asynchronous time series. Experiments on synthetic dataset
validate the superiory of SimTA over standard RNN-based approaches.
Furthermore, we experiment the proposed method on an in-house, ret-
rospective dataset of real-world non-small cell lung cancer patients un-
der anti-PD-1 immunotherapy. The proposed method achieves promising
performance on predicting the immunotherapy response. Notably, our
predictive model could further stratify low-risk and high-risk patients in
terms of long-term survival. A reference implementation in PyTorch is
open source at https://github.com/M3DV/SimTA.
Keywords: asynchronous time series · prognosis · immunotherapy.
1 Introduction
Modeling patient prognosis is a challenging but important topic in clinical re-
search, where researchers analyze and predict clinical outcomes including re-
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sponse to certain therapy (e.g., radiotherapy, chemotherapy, surgery, immunother-
apy for oncology), patient progression-free survival (PFS) and overall survival
(OS). Research efforts have been paid on seeking significant biomarkers, e.g.,
EGFR mutation for EGFR-TKI therapy [23], PD-L1 expression and tumor mu-
tational burden (TMB) for immunotherapy [5]. However, these biomarkers are
generally costly and invasive, and possibly dissatisfactory for novel therapy, e.g.,
anti-PD-1 and anti-PD-L1 immunotherapy [14]. With more novel revolutionary
therapy (including combination therapy [11]) available, a unified analytic frame-
work for modeling patient prognosis is urged.
We address this issue via emerging deep learning technology by mining clin-
ical data, e.g., electronic health records (EHR) [13]. Specifically, we focus on a
unified approach to model patient prognosis under certain therapy. Prior arts
are generally developed on a single data modality [10,16]. Besides, only a few
studies [18] take into account the temporal / serial information. In clinical prac-
tice, multi-modal temporal data is continuously generated with numerous kinds
of sensors and records. It is remarkably valuable to mine the easily accessi-
ble information to develop the prognosis prediction system, e.g., radiograph-
ics, laboratory and clinical information. We formalize the prognosis modeling
as a multi-modal asynchronous time series classification task, and propose
a MIA-Prognosis framework with Measurement, Intervention and Assess-
ment (MIA) information, where Measurement and Intervention information are
treated as inputs of multi-modal asynchronous time series to predict the Assess-
ment as ground truth (details in Sec. 2.1).
An algorithmic challenge is how to effectively and efficiently process multi-
modal asynchronous time series like clinical information. Binkowski et al. [1]
propose a gated CNN for asynchronous time series analysis, where asynchronous
time intervals are regarded as input features. This approach might not be suit-
able for the clinical scenario since it is not essentially asynchronous; data is
needed to learn representation for time intervals. What we need for real-world
clinical data processing is a natively asynchronous model, which is flexible and
light-weight to learn from expensive clinical data. Inspired by recent advances in
natural language processing (NLP), e.g., attention transformers [17,21,3] and rel-
ative position encoding [15], we propose a Simple Temporal Attention (SimTA)
module to process asynchronous time series, where attention matrix is learned
simply from the time intervals of asynchronous time series (details in Sec. 2.2).
The SimTA module is proven to be superior to standard RNN-based ap-
proaches in a synthetic asynchronous time series prediction dataset. Moreover,
we experiment the proposed MIA-Prognosis framework on an in-house retrospec-
tive dataset of real-world non-small cell lung cancer (NSCLC) under anti-PD-1
immunotherapy. Our predictive model achieves promising performance on pre-
dicting the immunotherapy response after 90 days. Notably, this model could
further stratify low-risk and high-risk patients in terms of long-term survival.
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2 Methods
2.1 MIA Prognosis: The Framework
Categorizing Clinical Information. In clinical practice, data of a numerous
variety of modalities is collected. Most medical data is unaligned in time steps,
which means that it has varying intervals between adjacent steps in time series.
Such limitations call for a unified framework that integrates asynchronous data
of different modalities. To address this issue, we first divide clinical information
into three categories according to data sources: measurement, intervention
and assessment, which defined our MIA-Prognosis framework. Measurement
data comes from medical examinations such as imaging data (computed to-
mography, ultrasound, X-ray), laboratory and genetic tests. Measurement is the
main information in our MIA-Prognosis framework. Interventions include ac-
tions such as injections and operations. Assessment evaluates the effectiveness
of interventions, e.g., Response Evaluation Criteria in Solid Tumors (RECIST)
[4], or 1-year overall survival rates. In this study, we use RECIST to obtain
the “ground truth”5 of therapy response, where complete response (CR), partial
response (PR), stable disease (SD) are regarded as response (R), and PD (pro-
gressive disease) is regarded as non-response (non-R). Note that measurement,
intervention and assessment can also be categoried into either serial or static
data, which depends on its status over time. These categorizations are the basis
of our framework’s capability of integrating heterogeneous multi-modal data.
Model Overview. We propose a framework that integrates multi-modal data in
asynchronous time series, named MIA-Prognosis. Fig. 1 gives an overall descrip-
tion of our framework. Due to the fact that clinical data of different modalities is
usually unaligned in time, it is impractical to simply concatenate these vectors
together and pad zeroes at the time step where a certain modality is missing.
Therefore, we process each modality independently in our framework. We pass
serial data of each modality through its own SimTA module, which outputs
a summary vector. The summary vector is added with a temporal encoding
(adapted from position encoding [17]) of time intervals between the assessment
time and the last time stamp. Static data goes through a multi-layer perceptron
(MLP) that encodes it in high-dimensional embedding. We then concatenate
summary vectors of serial data with static embedding, and input the concate-
nated vector into another MLP to give the final prediction of therapy response
(R: response / non-R: non-response) after an unobserved period.
Existing deep sequential models, such as recurrent neural network (RNN),
assume that time series data is synchronous in nature. However, this assumption
does not hold in the context of clinical practice. Here we introduce a new mod-
ule to help us process asynchronous data, named SimTA. Inspired by recent ad-
vances in natural language processing (NLP), e.g., attention transformers [17,3]
and relative position encoding [15], SimTA utilizes time interval information of
5 RECIST is not theoretecally perfect. We refer to “ground truth” in a clinical sense.
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Fig. 1: The MIA-Prognosis framework, with Measurement, Intervention and As-
sessment information. The asynchronous time series is encoded by the proposed
Simple Temporal Attention (SimTA) module into a summary vector. The sum-
mary vector is further added with a temporal encoding of time intervals between
the assessment time and the last time stamp (δt1 and δt2). Together with static
information, these features predict the therapy response (R / non-R) after an
unobserved period.
asynchronous series to generate attention matrix, capturing temporal relation-
ships between asynchronous time steps. It is worth noting that the latest steps
in time series of different modalities are not likely to coincide with each other.
In such cases, we use temporal encoding to make use of this information.
2.2 Simple Temporal Attention for Asynchronous Time Series
Simple Temporal Attention (SimTA) is the key factor that enables our framework
to process asynchronous times series. Let X ∈ RT×C be an asynchronous time
series of length T , and τ = [τ1, τ2, . . . , τT−1] ∈ RT−1 be the time interval vector
between any adjacent time steps. A general formula of a single SimTA module
can be described as:
SimTA(X, τ ) = softmax(A)σ(f(X)), (1)
where σ denotes an activation function of our choice, and f is a fully-connected
layer. A = S(X, τ) ∈ RT×T is the attention matrix that encodes relations be-
tween any two time steps. Matrix A can be calculated using any edge-aware
attention mechanism, e.g., multi-head self attention [17] with relative position
encoding [15]. In this study, we use an extremely simplified version that only
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encodes linearly time intervals, which is validated effective in our experiments:
A = S(τ ) =

0, −∞, −∞, . . . −∞
−λτ1 + β, 0, −∞, . . . −∞
−λ(τ1 + τ2) + β, −λτ2 + β, 0, . . . −∞
...
...
...
. . .
...
−λ∑T−11 τi + β, −λ∑T−12 τi + β, −λ∑T−13 τi + β, . . . 0
 ,
(2)
where λ ∈ R+ and β ∈ R are trainable parameters that apply a linear transfor-
mation on τ . The simplicity of this attention mechanism can help us cope with
overfitting as well, considering we only have limited amount of data. The formula
is based on the assumption that the more recent time steps should have stronger
correlations with the current time step than further ones. Complex temporal in-
formation can be captured by stacking multiple SimTA modules. The complete
SimTA model pipeline is a SimTA block of one or multiple SimTA modules,
which outputs a summary vector, followed by an MLP that outputs the final
prediction with softmax activation. To the best of our knowledge, the proposed
SimTA is the first study to introduce attention mechanism to asynchronous time
series analysis with proven effectiveness.
2.3 Counterpart Approaches
To demonstrate SimTA’s capability of learning asynchronous temporal relations,
we bring in LSTM (Long Short-term Memory) [9,7] as comparison. LSTM is a
special type of RNN designed to capture relations over extended time intervals
in sequences. In our experiments, we use LSTM models with a comparable size
and the same training configuration as SimTA. Let Xi be the value of the time
series at time step ti. Three LSTM approaches are tested, which differ in their
input: (1) Only Xi; (2) Xi and time intervals τi; (3) Xi and time stamps ti. We
mark them as LSTM, LSTM(i) and LSTM(s), respectively.
3 Experiments
3.1 Proof of Concept on Synthetic Dataset
We first validate the superiority of the proposed SimTA over RNN on asyn-
chronous time series using a synthetic dataset.
Dataset and Experiment Settings. The synthetic dataset consists of the
summation of N trigonometric functions with random periods. Each time series
is computed as:
Xt =
N∑
j=1
[αj sin(ωjpit+ bj) + βj ] + η (3)
where N is the number of trigonometric functions involved.  is a white noise
following the standard normal distribution, whose magnitude is controlled by a
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Fig. 2: The synthetic time series and MSE loss curves of LSTM, LSTM(i),
LSTM(s) and the proposed SimTA. Left: The illustration of a data sample.
Middle: Training MSE loss curves. Right: Validation MSE loss curves. We clip
the y axis in both loss curves for the sake of better visualization.
constant η. In our experiments, we choose N = 10 and η = 0.5. We generate
10,000 such asynchronous series, which are split in 80/20 for training/validation,
respectively. The training/validation data is sampled once from the predefined
distribution and fixed throughout the experiment.
During training, 10 different Xt are randomly sampled from each series. The
time intervals between any two adjacent points follow a uniform distribution be-
tween 0 and a maximum interval level I. The model is tasked to predict the next
3 points (+1,+2,+3) following the last one in the input. Fig. 2 shows a sample
series of the synthetic dataset. In our experiments, we compare performances of
SimTA and three LSTM models, which are LSTM, LSTM(i) and LSTM(s). For
LSTM(i) and LSTM(s), Xt and the time information are concatenated into one
vector. SimTA follows the model described in Sec. 2.2.
Results. We train all four models for 100 epochs. Fig. 2 shows the training and
validation mean squared error over the training phase. SimTA outperforms all
three LSTM models on both training and validation data. It achieves significantly
lower MSE (2.197 on SimTA and 6.427 on all LSTM approaches) compared with
LSTM. The time information does help LSTM(i) and LSTM(s) to converge
faster than vanilla LSTM, but all three end up with errors at the same level. It
is worth noting that the LSTM model variants underfit the training set. From
the observations above, we conjecture that the proposed SimTA outperforms
existing standard sequential models such as LSTM for asynchronous time series.
3.2 Predicting Response to Anti-PD-1 Immunotherapy for
Non-Small Cell Lung Cancer (NSCLC)
Background. Lung cancer is the most commonly diagnosed cancer worldwide.
According to [2], lung cancer accounts for 18.4% of the global cancer deaths
in 2018. NSCLC makes up 80%-85% of these cases. Deep learning has shown
its potential in precision medicine for lung cancer [25,24,22,19]. Recently, im-
munotherapy has been proven to remarkably increase the overall survival and
the life quality of patients with a variaty of cancers, including NSCLC. However,
only a small percentage of patients benefit from immunotherapy and show lasting
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responses. There has been research on the identification of response predictors,
whereas most of the effort are focused on biopsy analyses and serum biomark-
ers, e.g., PD-L1 expression and tumor mutation burden (TMB) for first-line
immunotherapy. These methods are expensive, invasive, and not always consis-
tently associated with tumor responses. Furthermore, no biomarker is available
for predicting second-line NSCLC immunotherapy outcome so far . Such lim-
itations emphasize the necessity for convenient, economical and non-invasive
indicators, especially for second-line immunotherapy treatment.
Dataset and Experiment Settings. In this retrospective study, 99 patients
with advanced or metastatic stage IIIB and IV NSCLC under second-line im-
munotherapy are included. The dataset includes 793 CT scans, 1335 laboratory
blood tests, 99 clinical data, and 320 response evaluations as per RECIST1.1 [4].
All data is further categorized into serial data and static data.
The CT scans are labelled by one radiologist with 8 years of experience, by
manually segmenting the volume of interest (VOI) of the target lesion in each
scan. An oncologist with 30 years of experience reviewed and confirmed the
segmentation. CT volumes and segmentation masks are resampled to uniform
spacing (1mm× 1mm× 1mm), with B-spline interpolation for CT volumes and
nearest-neighbor interpolation for VOI masks. We use radiomics features [6] to
represent the radiological features due to limited number of samples. With large
data available, a fully end-to-end CNN could also be used as the feature extrac-
tor. 107 radiomics features are extracted from each VOI using PyRadiomics [8].
Radiomics features are treated as serial data unless there is only one CT exam-
ination. The serial blood test features are in 22 dimensions and static clinical
information features are in 18 dimensions. All categorical features are encoded
in one-hot vectors. Numeric features are normalized by removing the mean and
scaling to unit variance to ensure stable training and faster convergence. Inter-
vention information is one-hot encoded (i.e., a binary flag at a time step). Serial
radiomics, laboratory blood test and intervention is asynchronous in time.
In our experiments, models are tasked to output binary predictions of R
(response) or Non-R (non-response) of each response evaluation, with static data
and all serial data before 90 days prior to time of response assessment. We use
binary cross entropy (BCE) as the loss function. SimTA model is optimized
with Adam optimizer [12]. We split the 99 patients into 3-fold (33 patients
in each fold), and perform 3-fold cross validation for evaluating our method.
Hyperparameters of model structure and training configuration are chosen using
a grid search with bootstrap on the training dataset in each cross validation fold.
To verify the effectiveness of SimTA on asynchronous time series, we include
LSTM, LSTM(i) and LSTM(s) in our ablation study as comparison. LSTM
models of comparable parameters are trained under similar setting.
We further associate model prediction with clinical survival benefits, specifi-
cally, overall survival (OS) and progression-free survival (PFS). A cutoff value of
0.5 is used for stratifying patients into high-risk and low-risk groups. The serial
data before 90 days prior to time of response assessment is used as input to the
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Table 1: Model performance of on predicting immunotherapy response, including
standard RNN approaches (LSTM, LSTM(i), LSTM(s)) instead of the proposed
SimTA, and our methods with multi-modal and single-modal inputs.
Methods LSTM LSTM(i) LSTM(s) Ours Ours w/o radiomics Ours w/o lab
AUC 0.71 0.71 0.70 0.80 0.47 0.58
timeline timeline
Fig. 3: Model performance on predicting NSCLC patient survival under anti-PD-
1 immunotherapy. Left: Patient survival curve visualized by Kaplan-Meier (K-
M) plot of progression-free survival (PFS), p-value of log-rank test to high/low-
risk groups is < 0.01. Right: K-M plot of overall survival (OS), with p < 0.01.
trained model. Kaplan-Meier analysis and log-rank test for the survival analysis
validate the effectiveness of our method in terms of patient survival.
Results. As depicted in Table 1, promising results are observed in predict-
ing immunotherapy outcome using the proposed framework. The area under
curve (AUC) of receiver operating characteristic (ROC) curve is 0.80 with our
MIA-Prognosis framework, whereas vanilla LSTM, LSTM(i) and LSTM(s) are
achieving 0.71, 0.71 and 0.70 AUC respectively. The LSTM counterparts does
not totally fail in this case because the patients are taking CT scans and blood
tests on a fairly regular schedule, the interval variance is mostly smaller than
seven days. Still, SimTA outperforms LSTM by a large margin in this “mildly”
asynchronous serial data modelling task. We also validate the necessity of multi-
modal input. Without radiomics feature or laboratory blood test results, our
framework reaches very low AUC of 0.47 and 0.58 respectively, suggesting the
significance of multi-modal model in this task. Moreover, as shown in Fig. 3,
the p-values for Kaplan-Meier analysis are significant in both PFS and OS tests.
Therefore, our predictive model could further stratify the low- and high-risk
patients in terms of patient survival.
4 Conclusion and Further Work
In this paper, we focus on a unified deep learning framework to predict therapy
response, with easily accessible clinical data. The proposed framework named
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MIA-Prognosis utilizes clinical information including Measurement, Intervention
and Assessment to model patient prognosis. We also propose a Simple Tempo-
ral Attention (SimTA) module to process the asynchronous time series. The
proof-of-concept experiments validate the superiority of SimTA over standard
RNN approaches in asynchronous time series analysis. Moreover, our method
is proven effective on an in-house dataset on predicting response to anti-PD-1
immunotherapy for real-world non-small cell lung cancer (NSCLC) patients. Im-
portantly, our predictive model is associated with long-term patient survival in
terms of progression-free survival (PFS) and overall survival (OS).
In future studies, it is valuable to apply the proposed MIA-Prognosis frame-
work on other therapy and diseases. On the other hand, it is also important
to design efficient and effective non-linear temporal attention module to en-
hance temporal relation learning of SimTA. Besides, a fully end-to-end model
with CNN-based Radiomics [20] to encode the signature of radiographic fea-
tures is worth exploring. Furthermore, it is interesting to explain what the MIA-
Prognosis models from data-driven approaches.
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